Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F
Nelly ZIADE 🍀 Nellziade
2 months ago
Have you ever thought of diclofenac as an environmental pollutant?
Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026
@rheumnow https://t.co/RJWB6DmiZh
sheila RHEUMarampa
2 months ago
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw
Antoni Chan MD (Prof) synovialjoints
2 months ago
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up.
Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Nelly ZIADE 🍀 Nellziade
2 months ago
Live vaccinations in infants antenatally exposed to bDMARDs
⬇️⬇️
#WIN session @lauraandreoli80
#EULAR2026 @RheumNow https://t.co/84MCwb2fbT
Mrinalini Dey DrMiniDey
2 months ago
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Treatment-refractory RA is more common than we sometimes admit. Roughly 11% of patients fail multiple b/tsDMARD classes, and for the ACPA-positive subset, rituximab has long been the fallback. It works, but it rarely produces durable disease-free intervals. CD19 CAR T-cell therapy was always going to be the question that followed the SLE data. Until EULAR 2026, that question had no prospective answer. The plenary session changed that.
